<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11640">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00556894</url>
  </required_header>
  <id_info>
    <org_study_id>CF101-203RA</org_study_id>
    <nct_id>NCT00556894</nct_id>
  </id_info>
  <brief_title>Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Safety and Efficacy of Daily CF101 Administered Orally, When Added to Weekly Methotrexate, in Patients With Active Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Can-Fite BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Can-Fite BioPharma</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will test the hypothesis that the addition of CF101, a novel anti-inflammatory
      agent, will improve the clinical condition of patients with rheumatoid arthritis who still
      have active joint inflammation despite taking methotrexate for at least 6 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a multi-center, randomized, double-blind, parallel-group, placebo-controlled,
      dose-finding study in which patients with active RA despite receiving methotrexate for at
      least 6 months (at unchanged doses for &gt;=2 months) will be randomized to the addition of
      either CF101 0.1 mg, CF101 1 mg, or placebo given orally q12h for 12 weeks. Screening
      examinations will occur within 1 month prior to dosing. Washout of other disease-modifying
      antirheumatic drugs (DMARDs) (with the exception of hydroxychloroquine), including
      biological agents, will occur prior to dosing; if washout is necessary, patients must
      re-qualify for inclusion following the washout. Doses of nonsteroidal anti-inflammatory
      drugs (NSAIDS) and corticosteroids must be stable for &gt;=1 month prior to dosing and remain
      so during protocol participation. Disease activity will be assessed using swollen and tender
      joint counts, physician and patient global assessments (by visual analog scale, VAS),
      patient reported pain (by VAS), a Health Assessment Questionnaire (HAQ) Disability Index
      (DI), Westergren erythrocyte sedimentation rate (ESR, Screening, Weeks 0 and12), and
      C-reactive protein (CRP) levels. Assessments will take place at Screening, Baseline (Week
      0), and at Weeks 2, 4, 8, and 12.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>ACR20</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>ACR20 response at endpoint at 12 weeks using non-responder imputation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACR 20/50/70, ITT and Evaluable Population, Last Observation Carried Disease Activity Score (DAS28) Change From Baseline at Each Visit in the Efficacy Parameters</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>ACR20/50/70 responses over time (intent-to-treat [ITT], last observation carried forward [LOCF]), mean changes in individual components of the ACR response criteria, DAS28, European League Against Rheumatism (EULAR) responses</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CF101 0.1 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CF101 1 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CF101</intervention_name>
    <description>orally q12h</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>IB-MECA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females ages 18-75 years

          -  Meet the criteria of the American College of Rheumatology for RA (Arnett FC et al.
             Arthritis Rheum 1988;31:315-324; refer to Appendix 1. diagnostic criteria for
             Rheumatoid Arthritis)

          -  Not bed- or wheelchair-bound

          -  Active RA, as indicated by the presence of (a) &gt;=6 swollen joints (28 joint count);
             AND (b) &gt;=6 tender joints (28 joint count); AND either: (c) Westergren ESR of &gt;=28
             mm/hour; OR (d) CRP level above the upper limit of normal for the central reference
             laboratory

          -  Treatment with weekly oral or parenteral methotrexate for &gt;=6 months prior to
             baseline

          -  Methotrexate route of administration has been unchanged for &gt;=2 months prior to
             baseline

          -  Dose of methotrexate has been stable at 15-25 mg/week for &gt;=2 months, and is expected
             to remain stable throughout the study; the stable dose of methotrexate may
             alternatively be 10-12.5 mg/week if documented toxicity has precluded a higher dose

          -  If taking hydroxychloroquine or chloroquine, administration duration has been for &gt;=3
             months and dose has been stable for &gt;=2 months prior to baseline

          -  If taking a nonsteroidal anti-inflammatory agent (NSAID), dose has been stable for at
             least 1 month prior to baseline, and will remain unchanged during protocol
             participation

          -  If taking an oral corticosteroid, dose is &lt;10 mg/day prednisone or equivalent, has
             been stable for at least 1 month prior to the stabilization period, and will remain
             stable through the stabilization and entire treatment and follow-up period

          -  Negative screening serum pregnancy test for female patients of childbearing potential

          -  Females of childbearing potential must utilize, throughout the course of the trial, 2
             methods of contraception deemed adequate by the Investigator (for example, oral
             contraceptive pills plus a barrier method)

        Exclusion Criteria:

          -  Receipt of any of the following for at least a 1 month stabilization period prior to
             dosing: sulfasalazine, oral or injectable gold, azathioprine, minocycline,
             penicillamine, anakinra

          -  Receipt of etanercept for at least a 6 week period prior to dosing

          -  Receipt of cyclosporine, infliximab or adalimumab for at least a 2 month period prior
             to dosing

          -  Receipt of leflunomide for at least a 2 month period prior to screening, unless
             patient has undergone cholestyramine washout at least 1 month prior to dosing

          -  Receipt of cyclophosphamide for at least a 6 month period prior to dosing

          -  Receipt of rituximab at any previous time

          -  Participation in a previous trial CF101 trial

          -  Use of oral corticosteroids &gt;10 mg of prednisone, or equivalent, per day

          -  Change in NSAID dose level for 1 month prior to dosing

          -  Change in oral corticosteroid dose level during the 1 month prior to, or during, the
             stabilization period vChange in hydroxychloroquine or chloroquine dose level during
             the 2 months prior to, or during, the stabilization period

          -  Receipt of parenteral or intra-articular corticosteroids during the 1 month prior to,
             or during, the stabilization period

          -  Significant cardiac arrhythmia or conduction block, congestive heart failure, or any
             other evidence of clinically significant heart disease; other clinically significant
             findings on screening electrocardiogram (ECG)

          -  Hemoglobin level &lt;9.0 gm/dL at the screening visit

          -  Platelet count &lt;125,000/mm3 at the screening visit

          -  White blood cell count &lt;3000/mm3 at the screening visit

          -  Serum creatinine level outside the central laboratory's normal limits at the
             screening visit

          -  Liver aminotransferase (ALT and/or AST) levels greater than 1.25 times the central
             laboratory's upper limit of normal at the screening visit

          -  Significant acute or chronic medical or psychiatric illness that, in the judgment of
             the Investigator, could compromise patient safety, limit the patient's ability to
             complete the study, and/or compromise the objectives of the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael H Silverman, MD</last_name>
    <role>Study Director</role>
    <affiliation>BioStrategics Consulting Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinic of Rheumatology at MHAT 'Sveti Georgi'</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Rheumatology at MHAT 'Sveti Ivan Rilski'</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of internal diseases at NMTH 'Tzar Boris Treti'</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Clinic of Internal Diseases at MHAT 'Stara Zagora'</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Rheumatology at MHAT 'Sveta Marina' - Varna</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50005</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Rheumatology</name>
      <address>
        <city>Prague</city>
        <zip>12850</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumotology Out-patient Clinic</name>
      <address>
        <city>Zlin</city>
        <zip>76001</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haemek Medical Center</name>
      <address>
        <city>Afula</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barzilai Medical Center</name>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Har-Hazofim Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar-Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Zespolony w Elblagu</name>
      <address>
        <city>Elblag</city>
        <zip>82300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej</name>
      <address>
        <city>Lublin</city>
        <zip>20607</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Zespol Reumatologiczny w Sopocie</name>
      <address>
        <city>Sopot</city>
        <zip>81967</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 1 P.A.M. w Szczecinie</name>
      <address>
        <city>Szczecin</city>
        <zip>71252</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej &quot;NASZ LEKARZ&quot;</name>
      <address>
        <city>Torun</city>
        <zip>87100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Rheumatology - Belgrade</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Prevention, Treatment, and Rehabilitation of Rheumatoid and Cardiovascular Diseases Niska Banja</name>
      <address>
        <city>Niska Banja</city>
        <zip>18205</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Municipal Clinical Hospital nÂº1</name>
      <address>
        <city>Donetsk</city>
        <zip>83114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv Central Municipal Hospital</name>
      <address>
        <city>Kiev</city>
        <zip>01023</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital N12</name>
      <address>
        <city>Kiev</city>
        <zip>01103</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Scientific Centre of AMS of Ukraine</name>
      <address>
        <city>Kiev</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>O.O. Bogomolets National Medical University</name>
      <address>
        <city>Kiev</city>
        <zip>04053</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnitsya Regional Clinical Hospital</name>
      <address>
        <city>Vinnycia</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>Israel</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Former Serbia and Montenegro</country>
  </removed_countries>
  <verification_date>August 2011</verification_date>
  <lastchanged_date>February 24, 2015</lastchanged_date>
  <firstreceived_date>November 8, 2007</firstreceived_date>
  <firstreceived_results_date>February 24, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CF101 0.1mg</title>
          <description>CF101 0.1mg orally q12 for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>CF101 1mg</title>
          <description>CF101 1mg orally q12 for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Matching placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="87"/>
                <participants group_id="P3" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="68"/>
                <participants group_id="P3" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>regulatory decision in Bulgaria</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Change in therapy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CF101 0.1mg</title>
          <description>CF101: orally q12h</description>
        </group>
        <group group_id="B2">
          <title>CF101 1mg</title>
          <description>CF101: orally q12h</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>CF101: orally q12h</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="82"/>
                <measurement group_id="B2" value="87"/>
                <measurement group_id="B3" value="84"/>
                <measurement group_id="B4" value="253"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="66"/>
                <measurement group_id="B2" value="69"/>
                <measurement group_id="B3" value="69"/>
                <measurement group_id="B4" value="204"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="15"/>
                <measurement group_id="B4" value="49"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="55" lower_limit="24" upper_limit="75"/>
                <measurement group_id="B2" value="54" lower_limit="25" upper_limit="75"/>
                <measurement group_id="B3" value="54" lower_limit="33" upper_limit="73"/>
                <measurement group_id="B4" value="54" lower_limit="24" upper_limit="75"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="68"/>
                <measurement group_id="B2" value="64"/>
                <measurement group_id="B3" value="71"/>
                <measurement group_id="B4" value="203"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="23"/>
                <measurement group_id="B3" value="13"/>
                <measurement group_id="B4" value="50"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Serbia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="20"/>
                <measurement group_id="B4" value="62"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Ukraine</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
                <measurement group_id="B2" value="26"/>
                <measurement group_id="B3" value="26"/>
                <measurement group_id="B4" value="74"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Israel</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="8"/>
                <measurement group_id="B4" value="26"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Bulgaria</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
                <measurement group_id="B2" value="32"/>
                <measurement group_id="B3" value="30"/>
                <measurement group_id="B4" value="91"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>ACR20</title>
        <description>ACR20 response at endpoint at 12 weeks using non-responder imputation.</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>CF101 0.1mg</title>
          </group>
          <group group_id="O2">
            <title>CF101 1mg</title>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="66"/>
                  <measurement group_id="O2" value="68"/>
                  <measurement group_id="O3" value="65"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>ACR20</title>
            <description>ACR20 response at endpoint at 12 weeks using non-responder imputation.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="66"/>
                  <measurement group_id="O2" value="68"/>
                  <measurement group_id="O3" value="65"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR 20/50/70, ITT and Evaluable Population, Last Observation Carried Disease Activity Score (DAS28) Change From Baseline at Each Visit in the Efficacy Parameters</title>
        <description>ACR20/50/70 responses over time (intent-to-treat [ITT], last observation carried forward [LOCF]), mean changes in individual components of the ACR response criteria, DAS28, European League Against Rheumatism (EULAR) responses</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CF101 0.1mg</title>
          <description>CF101 0.1mg q12 for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>CF101 1mg</title>
          <description>CF101 1mg q12 for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Matching Placebo q12 for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <description>Pancytopenia</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Microcytic anemia</sub_title>
                <description>HYPOCHROMIC MICROCYTIC ANEMIA III ST.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <description>OEDEMA OF BOTH EYELIDS WITH CARIAL RASH ON THE NECK</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea and Diarrhoea</sub_title>
                <description>Nausea and Diarrhoea</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase and Aspartate aminotransferase increased</sub_title>
                <description>Elevated ALAT and ASAT</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Nausea</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pnina Fishman, PhD</name_or_title>
      <organization>Can-Fite Biopharma</organization>
      <phone>011972 39241114</phone>
      <email>pnina@canfite.co.il</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
